GLPwatch
Papers (12034)
Page 67 of 201, ranked by citation count.
- Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists.
- Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
- Tirzepatide for overweight and obesity management.
- Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function.
- Strain Differences Determine the Suitability of Animal Models for Noninvasive In Vivo Beta Cell Mass Determination with Radiolabeled Exendin.
- Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.
- Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies.
- Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro).
- Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)-a structured summary of a study protocol for a randomized controlled study.
- Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes.
- GLP-1 receptor agonists: A review of glycemic benefits and beyond.
- Stability of exenatide in poly(D,L-lactide-co-glycolide) solutions: a simplified investigation on the peptide degradation by the polymer.
- Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations.
- Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management.
- Association of semaglutide treatment with coronary artery inflammation in type 2 diabetes mellitus patients: a retrospective study based on pericoronary adipose tissue attenuation.
- Tirzepatide and exercise training in obesity.
- The effect of glucagon-like Peptide-1 receptor agonists on measures of suicidality: A systematic review.
- The active GLP-1 analogue liraglutide alleviates H9N2 influenza virus-induced acute lung injury in mice.
- Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus.
- Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity.
- Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
- Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review.
- Semaglutide improves cognitive function and neuroinflammation in APP/PS1 transgenic mice by activating AMPK and inhibiting TLR4/NF-κB pathway.
- A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders.
- Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.
- Obesity medications: A narrative review of current and emerging agents.
- The permissive effects of glucose on receptor-operated potentiation of insulin secretion from mouse islets: a role for ERK1/2 activation and cytoskeletal remodelling.
- Synthesis and biological evaluation of an <sup>111</sup>In-labeled exendin-4 derivative as a single-photon emission computed tomography probe for imaging pancreatic β-cells.
- Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway.
- Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery.
- Evaluation of the risk of fracture in type 2 diabetes mellitus patients with incretins: an updated meta-analysis.
- Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential.
- An experimental study of exenatide effects on renal injury in diabetic rats1.
- Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting.
- Efficacy of liraglutide in a real-life cohort.
- Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study.
- Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart.
- Liraglutide for the treatment of type 2 diabetes.
- The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity-A systematic review.
- Efficacy of Intragastric Balloon versus Liraglutide as Bridge to Surgery in Super-Obese Patients.
- Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration.
- C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.
- Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington's Disease.
- Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis.
- Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom.
- FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea.
- Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice.
- Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population.
- Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
- Anti-obesity drugs' side effects: what we know so far.
- Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials.
- iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes.
- Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature.
- Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice.
- Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes.
- Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study.
- The glucagon-like peptide-1 analogue liraglutide promotes autophagy through the modulation of 5'-AMP-activated protein kinase in INS-1 β-cells under high glucose conditions.
- Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study.
- Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis.
- Normalisation of glucose metabolism by exendin-4 in the chronic phase after stroke promotes functional recovery in male diabetic mice.